CONNECT1-EDO51: A 12-Week Open-Label Phase 2 Study to Evaluate PGN-EDO51 Safety and Efficacy in People with Duchenne Amenable to Exon 51 Skipping

Michelle Mellion[1], Hugh McMillan[2], Nicolas Chrestian[3], Hernan Gonorazky[4], Colleen O'Connell[5], Sarah Vacca[1], Mark Peterson[1], Bassem Morcos[1], Sejal Batra[1], Pallavi Lonkar[1], Ashling Holland[1], Jeffrey Foy[1], Sarah Lamore[1], Brijesh Garg[1], Shaoxia Yu[1], Greg Song[1], Jane Larkindale[1]

1. PepGen Inc, 2. Children's Hospital of Eastern Ontario (CHEO), ON, Canada 3. CHU De Quebec-Universite Laval QC, Canada
4.The Hospital for Sick Children (SickKids), ON, Canada 5. Dalhousie University Faculty of Medicine NS, Canada

Conflict of Interest

- I am a full-time employee of PepGen
- I receive compensation, stock and benefits from PepGen

PepGen's Enhanced Delivery Oligonucleotide (EDO) Technology is Engineered to Optimize Tissue Delivery and Nuclear Uptake of Therapeutic Oligonucleotides

PGN-EDO51 is PepGen's investigational clinical candidate for the treatment of Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping



PepGen's EDO: Up to 25X Higher Nuclear Uptake of Oligonucleotide vs PMO



In vitro staining image is shown with 10µM conc. of EDO23. C2C12 mouse cells were differentiated for 4 days into myotubes and treated with fluorescently tagged compounds for 24h. PMO: phosphorodiamidate morpholino oligomer

CONNECT1*: Designed to Establish Proof-of-Concept and Inform CONNECT2-EDO51 Clinical Trial

Design

- Open label clinical trial in Canada
- DMD patients (n=10) with exon 51 skippable mutation
- Ages ≥ 8 years
- Ambulatory and non-ambulatory

Endpoints

- Safety and tolerability
- Dystrophin
- Muscle tissue concentration of PGN-EDO51
- Exon skipping



IV administration every 4 weeks, DSMB: data safety and monitoring board

Baseline characteristics are detailed in poster 403P

* ClinicalTrials.gov number, NCT06079736

CONNECT1 5 mg/kg: Safety Profile[1]

MAD Period	n (%)
Any TEAEs, n (%)	3 (100)
Related to study drug	1 (33.3)
• Mild • Moderate • Severe	1 (33.3) 0 0
Serious Adverse Events (AEs)	0
AEs leading to dose modification/ discontinuation/interruption	0
AEs leading to death	0

- All treatment emergent adverse events (TEAEs) were mild and resolved
- Related TEAE was mild (abdominal pain, flatulence)
- No discontinuations, dose modifications or dose interruptions
  - All participants rolled over to the long-term extension study
- No sustained elevation in kidney biomarkers
- No changes in electrolytes
  - No hypomagnesemia or hypokalemia
- No changes in hepatic function
- No anemia or thrombocytopenia

At 5 mg/kg, a total of 25 doses have been administered (12 doses in the MAD period+13 doses in the LTE period)[2]

1. As of May 31, 2024
2. As of September 4, 2024

PGN-EDO51 Produced High Levels of Mean Exon Skipping and Promising Dystrophin Increase over Short Treatment Duration and with Few Doses







4 doses over 3 months

MHC: Myosin Heavy Chain, BL: Baseline, SEM: Standard Error of the Mean

Dosing Continues in Cohort 2 at 10 mg/kg[1]

- The emerging safety profile is favorable
- At 10 mg/kg, a total of 7 doses have been administered
- All treatment-related AEs were mild and have resolved without treatment
- Asymptomatic mild hypomagnesemia in one patient was observed and treated with oral supplementation
- No dose discontinuations, dose modifications or dose interruptions
- No SAEs
- No sustained elevation in kidney biomarkers
- No changes in hepatic function
- No hypokalemia, anemia or thrombocytopenia

1. As per the data obtained through September 4, 2024

CONNECT1 Key Takeaways

- PGN-EDO51 has a favorable safety profile to date[1]
- All participants at 5 mg/kg demonstrated increased dystrophin production and exon skipping at just 3 months and after 4 doses
- Results support that our EDO technology delivers high levels of oligonucleotides to the nucleus

For more details, you can visit our posters

403P CONNECT1-EDO51: A 12-week open-label Phase 2 study to evaluate PGN-EDO51 safety and efficacy in people with Duchenne amenable to exon 51 skipping

404P CONNECT2-EDO51: A Phase 2 placebo-controlled study to evaluate PGN-EDO51 safety and efficacy in people with Duchenne amenable to exon 51 skipping

1. As per the data obtained through September 4, 2024

Thank you!

All the study participants and their families

The clinical investigators and their teams

- Dr. Hugh McMillan, MD, MSc, FRCPC
  Children's Hospital of Eastern Ontario (CHEO)
- Dr. Hernan Gonorazky, MD, CSCN
  The Hospital for Sick Children (SickKids)
- Dr. Nicolas Chrestian, MD, FRCPC, CSCN
  CHU De Quebec-Universite Laval
- Dr. Colleen O'Connell, MD, FRCPC
  Dalhousie University Faculty of Medicine
- Dr. Kristina Joyal
  Children's Hospital Research Institute of Manitoba

The Duchenne patient communities